Form 4: Arcellx Director David Charles Lubner Granted Stock Options

Arcellx, Inc. Director David Charles Lubner was granted 9,174 stock options with an exercise price of $63.68, vesting by May 29, 2026, or the next annual meeting.

Summary

• Arcellx, Inc. Director David Charles Lubner was granted 9,174 stock options.
• The options have an exercise price of $63.68 per share.
• The options are for the purchase of Arcellx Common Stock.
• The grant date for this transaction was May 29, 2025.
• The options will expire on May 29, 2035.
• One hundred percent (100%) of the shares subject to the award will vest on the earlier of May 29, 2026, or the next annual meeting of stockholders, contingent on Mr. Lubner's continued service as a Service Provider.
• Following this transaction, Mr. Lubner beneficially owns 9,174 derivative securities.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive signal of aligning insider interests with shareholder value, though it's a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of stock options to Director David Charles Lubner aligns his interests with those of shareholders, incentivizing long-term company performance.
• The exercise price of $63.68 indicates a specific valuation at the time of the grant, reflecting the company's current share price.

Negatives

• No direct negatives are apparent from this Form 4 filing, as it reports a standard equity compensation grant.

Risks

• The vesting of the stock options is subject to the reporting person's continuing to be a Service Provider, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

The vesting schedule for the granted stock options indicates a forward-looking incentive for the director to remain with the company and contribute to its long-term success, with full vesting expected by May 29, 2026, or the next annual meeting.

Industry Context

This transaction is a routine equity compensation grant to a director, common practice in the biotechnology and pharmaceutical industries to attract and retain experienced leadership and align their incentives with company performance and shareholder value creation.

Related Party Transactions

• The grant of stock options to Director David Charles Lubner constitutes a related party transaction, as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with long-term shareholder value creation, as the options gain value only if the stock price increases above the exercise price.
• Employees: While not directly impacting all employees, this type of compensation structure for leadership can set a precedent for performance-based incentives within the company.

Next Steps

• The granted stock options will vest on the earlier of May 29, 2026, or the next annual meeting of stockholders, provided the director continues to serve.
• The director may exercise the vested options to acquire common stock at the exercise price of $63.68 per share before the expiration date of May 29, 2035.

Key Dates

Recommendation

Keywords

Arcellx, ACLX, SEC Form 4, Stock Options, Director Compensation, Equity Incentive Plan, Insider Transaction, David Charles Lubner, Biotechnology, Pharmaceuticals